Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers

Chemotherapy resistance is a huge barrier for head and neck cancer (HNC) patients and therefore requires close attention to understand its underlay mechanisms for effective strategies. In this review, we first summarize the molecular mechanisms of chemotherapy resistance that occur during the treatm...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in Oncology Vol. 11; p. 640392
Main Authors Kanno, Yuzuka, Chen, Chang-Yu, Lee, Hsin-Lun, Chiou, Jeng-Fong, Chen, Yin-Ju
Format Journal Article
LanguageEnglish
Published Frontiers Media SA 07.05.2021
Frontiers Media S.A
Subjects
chemotherapy
chemotherapy resistance
combination therapy
head and neck cancer
immunotherapy
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Oncology
RC254-282
Online AccessGet full text
ISSN2234-943X
2234-943X
DOI10.3389/fonc.2021.640392

Cover

Abstract Chemotherapy resistance is a huge barrier for head and neck cancer (HNC) patients and therefore requires close attention to understand its underlay mechanisms for effective strategies. In this review, we first summarize the molecular mechanisms of chemotherapy resistance that occur during the treatment with cisplatin, 5-fluorouracil, and docetaxel/paclitaxel, including DNA/RNA damage repair, drug efflux, apoptosis inhibition, and epidermal growth factor receptor/focal adhesion kinase/nuclear factor-κB activation. Next, we describe the potential approaches to combining conventional therapies with previous cancer treatments such as immunotherapy, which may improve the treatment outcomes and prolong the survival of HNC patients. Overall, by parsing the reported molecular mechanisms of chemotherapy resistance within HNC patient’s tumors, we can improve the prediction of chemotherapeutic responsiveness, and reveal new therapeutic targets for the future.
AbstractList Chemotherapy resistance is a huge barrier for head and neck cancer (HNC) patients and therefore requires close attention to understand its underlay mechanisms for effective strategies. In this review, we first summarize the molecular mechanisms of chemotherapy resistance that occur during the treatment with cisplatin, 5-fluorouracil, and docetaxel/paclitaxel, including DNA/RNA damage repair, drug efflux, apoptosis inhibition, and epidermal growth factor receptor/focal adhesion kinase/nuclear factor-κB activation. Next, we describe the potential approaches to combining conventional therapies with previous cancer treatments such as immunotherapy, which may improve the treatment outcomes and prolong the survival of HNC patients. Overall, by parsing the reported molecular mechanisms of chemotherapy resistance within HNC patient’s tumors, we can improve the prediction of chemotherapeutic responsiveness, and reveal new therapeutic targets for the future.
Chemotherapy resistance is a huge barrier for head and neck cancer (HNC) patients and therefore requires close attention to understand its underlay mechanisms for effective strategies. In this review, we first summarize the molecular mechanisms of chemotherapy resistance that occur during the treatment with cisplatin, 5-fluorouracil, and docetaxel/paclitaxel, including DNA/RNA damage repair, drug efflux, apoptosis inhibition, and epidermal growth factor receptor/focal adhesion kinase/nuclear factor-κB activation. Next, we describe the potential approaches to combining conventional therapies with previous cancer treatments such as immunotherapy, which may improve the treatment outcomes and prolong the survival of HNC patients. Overall, by parsing the reported molecular mechanisms of chemotherapy resistance within HNC patient's tumors, we can improve the prediction of chemotherapeutic responsiveness, and reveal new therapeutic targets for the future.Chemotherapy resistance is a huge barrier for head and neck cancer (HNC) patients and therefore requires close attention to understand its underlay mechanisms for effective strategies. In this review, we first summarize the molecular mechanisms of chemotherapy resistance that occur during the treatment with cisplatin, 5-fluorouracil, and docetaxel/paclitaxel, including DNA/RNA damage repair, drug efflux, apoptosis inhibition, and epidermal growth factor receptor/focal adhesion kinase/nuclear factor-κB activation. Next, we describe the potential approaches to combining conventional therapies with previous cancer treatments such as immunotherapy, which may improve the treatment outcomes and prolong the survival of HNC patients. Overall, by parsing the reported molecular mechanisms of chemotherapy resistance within HNC patient's tumors, we can improve the prediction of chemotherapeutic responsiveness, and reveal new therapeutic targets for the future.
Author Yin-Ju Chen
Hsin-Lun Lee
Jeng-Fong Chiou
Yuzuka Kanno
Chang-Yu Chen
AuthorAffiliation 1 Division of Molecular Regulation of Inflammatory and Immune Disease, Research Institute for Biomedical Sciences, Tokyo University of Science , Chiba , Japan
6 Taipei Cancer Center, Taipei Medical University , Taipei , Taiwan
8 Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University , Taipei , Taiwan
9 International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University , Taipei , Taiwan
2 Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science , Chiba , Japan
3 Graduate School of Medicine, The University of Tokyo , Tokyo , Japan
7 TMU Research Center of Cancer Translational Medicine, Taipei Medical University , Taipei , Taiwan
5 Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University , Taipei , Taiwan
4 Department of Radiation Oncology, Taipei Medical University Hospital , Taipei , Taiwan
10
AuthorAffiliation_xml – name: 8 Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University , Taipei , Taiwan
– name: 5 Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University , Taipei , Taiwan
– name: 7 TMU Research Center of Cancer Translational Medicine, Taipei Medical University , Taipei , Taiwan
– name: 1 Division of Molecular Regulation of Inflammatory and Immune Disease, Research Institute for Biomedical Sciences, Tokyo University of Science , Chiba , Japan
– name: 10 Translational Laboratory, Research Department, Taipei Medical University Hospital, Taipei Medical University , Taipei , Taiwan
– name: 3 Graduate School of Medicine, The University of Tokyo , Tokyo , Japan
– name: 4 Department of Radiation Oncology, Taipei Medical University Hospital , Taipei , Taiwan
– name: 6 Taipei Cancer Center, Taipei Medical University , Taipei , Taiwan
– name: 9 International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University , Taipei , Taiwan
– name: 2 Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science , Chiba , Japan
Author_xml – sequence: 1
  givenname: Yuzuka
  surname: Kanno
  fullname: Kanno, Yuzuka
– sequence: 2
  givenname: Chang-Yu
  surname: Chen
  fullname: Chen, Chang-Yu
– sequence: 3
  givenname: Hsin-Lun
  surname: Lee
  fullname: Lee, Hsin-Lun
– sequence: 4
  givenname: Jeng-Fong
  surname: Chiou
  fullname: Chiou, Jeng-Fong
– sequence: 5
  givenname: Yin-Ju
  surname: Chen
  fullname: Chen, Yin-Ju
BackLink https://cir.nii.ac.jp/crid/1871428067850297984$$DView record in CiNii
BookMark eNp9kc9rFTEQx4NUbK29e9yDBy_vmd_ZXAR51L5CW0EUvIVsMulL3U2eyT6h_3133QrWQ-eQGSbz_czA9zU6SjkBQm8JXjPW6g8hJ7emmJK15Jhp-gKdUMr4SnP24-if-hid1XqHp5ACE8xeoWPGMZWSqBO0vc49uENvS3MNbmdTrENtcmg2OxjyuINi9_fNV6ixjjY5aGJqtmB9Y5NvbsD9bDZzu9Q36GWwfYWzx3yKvn8-_7bZrq6-XFxuPl2tnGB8XIECGbDW1NNOMio4a4ngnQSlA-1CRzl4J7hibRe89EGSwLD3RDOLSacsO0WXC9dne2f2JQ623Jtso_nTyOXW2DJG14OxImilJKXBY94J2jLA0lHvgSjveZhYHxfW_tAN015IY7H9E-jTnxR35jb_Ni2Zz9YT4P0joORfB6ijGWJ10Pc2QT5UQwUjgjEl1TQql1FXcq0FgnFxtGPMMzn2hmAzu2pmV83sqllcnYT4P-Hf-56RvFskKcZpzfySVhFOWyxVKzDVSrecPQC1ZrBq
CitedBy_id crossref_primary_10_3389_fonc_2023_1231460
crossref_primary_10_3390_medicina59020286
crossref_primary_10_3390_cancers15184650
crossref_primary_10_3390_ijms24010338
crossref_primary_10_1038_s41420_024_01947_y
crossref_primary_10_3390_ijms22168881
crossref_primary_10_1002_lio2_952
crossref_primary_10_3390_cells12162083
crossref_primary_10_3390_medsci11010006
crossref_primary_10_1002_mco2_702
crossref_primary_10_1016_j_archoralbio_2023_105696
crossref_primary_10_1186_s13046_022_02267_8
crossref_primary_10_1016_j_jcis_2024_01_066
crossref_primary_10_3390_cells12101376
crossref_primary_10_3390_cancers14194761
crossref_primary_10_1177_00220345241309624
crossref_primary_10_3390_cancers14174217
crossref_primary_10_1002_jsfa_13664
crossref_primary_10_1186_s40364_022_00433_w
crossref_primary_10_3390_ijms241713385
crossref_primary_10_1016_j_bbcan_2022_188772
crossref_primary_10_1186_s43141_023_00468_y
crossref_primary_10_1016_j_actbio_2022_06_017
crossref_primary_10_1016_j_prp_2023_154457
crossref_primary_10_1021_acsptsci_4c00518
crossref_primary_10_37349_etat_2023_00184
crossref_primary_10_1002_btm2_10741
crossref_primary_10_1177_00220345241261982
crossref_primary_10_1049_mna2_70004
crossref_primary_10_1016_j_canlet_2023_216119
crossref_primary_10_1002_cnr2_70023
crossref_primary_10_1002_hed_27803
crossref_primary_10_1016_j_tice_2025_102736
crossref_primary_10_3389_fimmu_2022_933547
crossref_primary_10_3390_cancers14102355
crossref_primary_10_1038_s41598_024_75861_9
crossref_primary_10_1186_s13005_022_00322_5
crossref_primary_10_1016_j_drudis_2025_104339
crossref_primary_10_1021_acs_chemrestox_2c00233
crossref_primary_10_2174_0118715206308864240823095507
crossref_primary_10_3389_fonc_2022_1044699
crossref_primary_10_3390_ijms22158199
crossref_primary_10_3390_cells11091581
crossref_primary_10_1016_j_saa_2025_125726
crossref_primary_10_32074_1591_951X_1085
crossref_primary_10_1038_s41416_023_02167_4
Cites_doi 10.1002/hed.23813
10.3892/mmr.2015.3768
10.1038/cddis.2017.271
10.1016/j.biopha.2017.04.043
10.1158/0008-5472.CAN-12-0953
10.1016/j.oraloncology.2010.11.011
10.1158/0008-5472.CAN-14-3098
10.1016/j.devcel.2009.06.016
10.1002/cncr.27498
10.1007/s10495-017-1375-1
10.1016/j.molmed.2015.04.001
10.1371/journal.pone.0108908
10.7554/eLife.47327
10.3390/molecules13081551
10.1083/jcb.143.2.547
10.1111/jop.12607
10.1038/s41586-019-1730-1
10.1038/cddis.2017.53
10.1038/nrc.2016.58
10.2174/156800910793605866
10.1093/annonc/mdu367
10.1016/j.tips.2017.02.001
10.2147/OTT.S237456
10.1074/jbc.M414477200
10.1038/nrc1317
10.1038/nrc2167
10.1155/2016/5378567
10.1093/oxfordjournals.annonc.a058903
10.1056/NEJMoa1602252
10.1038/s12276-018-0202-2
10.1038/nrm830
10.1038/375424a0
10.1056/NEJMra1715715
10.1517/14728220903460340
10.1016/S0140-6736(19)32591-7
10.1186/1479-5876-9-31
10.1038/s41698-017-0008-z
10.1186/s40425-016-0163-8
10.1038/s41598-018-20930-z
10.12659/MSM.923799
10.1073/pnas.162491399
10.3892/or.2017.5584
10.1016/j.dnarep.2015.04.002
10.1083/jcb.141.5.1181
10.3892/mmr.2016.5473
10.1200/JCO.2005.02.4646
10.1073/pnas.0610117104
10.1054/drup.1999.0108
10.3390/ijms20174136
10.1111/j.1600-0714.2011.01066.x
10.6061/clinics/2018/e478s
10.3892/ol.2018.7783
10.1038/s41572-020-00224-3
10.2741/3653
10.1038/cr.2007.19
10.3390/cancers11050616
10.1073/pnas.71.9.3649
10.1056/NEJMoa071028
10.1016/j.ccr.2005.03.003
10.1200/JCO.2018.79.0543
10.1158/1535-7163.MCT-10-0552
10.1038/s41598-018-35860-z
10.1038/sj.onc.1206934
10.1038/bjc.2011.387
10.1038/nrc2789
10.1186/s12885-019-5664-7
10.1021/bi00400a016
10.1093/annonc/mdf268
10.1093/jjco/hyaa220
10.1038/nrd3627
10.1038/onc.2008.302
10.1038/onc.2011.384
10.1016/S1470-2045(20)30327-2
10.2214/AJR.11.6953
10.1038/sj.onc.1207374
10.1038/cddis.2013.428
10.7150/jca.16720
10.1158/1078-0432.CCR-05-1583
10.1517/14712590902735795
10.1200/JCO.2006.07.2587
10.1038/nrc1412
10.1200/JCO.2007.15.1613
10.1158/1078-0432.CCR-08-0746
10.1093/annonc/mds581
10.1002/jcp.1041040305
10.1007/s10555-007-9045-3
10.1016/j.canlet.2017.05.022
10.1056/NEJMoa070956
10.1056/NEJMoa0802656
10.1002/path.4383
10.2174/1568009033333754
10.1200/JCO.2004.00.1990
10.1007/s00018-008-8557-5
10.1016/j.oraloncology.2015.02.094
10.1016/S0021-9258(18)68949-5
10.1038/sj.onc.1210681
10.1016/j.bbrc.2011.12.047
10.1002/pros.23476
10.1016/j.ejca.2012.04.013
10.1002/hed.21071
10.1038/nrd2130
10.1038/nrd1601
10.1021/bi00700a012
10.6004/jnccn.2014.0142
10.1038/sj.bjc.6604464
10.3322/caac.21492
10.1016/j.oraloncology.2018.04.008
10.1111/cas.12223
10.1038/nrc1074
10.1172/JCI119642
10.1016/j.radonc.2009.04.014
10.1007/s13402-017-0365-1
10.1158/2326-6066.CIR-17-0235
10.1038/s12276-020-0380-6
10.1371/journal.pone.0031601
10.1038/nrc3792
10.1093/annonc/mdw376.02
10.1016/j.canlet.2004.11.049
10.1083/jcb.200805072
10.1016/j.jinorgbio.2004.05.006
ContentType Journal Article
Copyright Copyright © 2021 Kanno, Chen, Lee, Chiou and Chen.
Copyright © 2021 Kanno, Chen, Lee, Chiou and Chen 2021 Kanno, Chen, Lee, Chiou and Chen
Copyright_xml – notice: Copyright © 2021 Kanno, Chen, Lee, Chiou and Chen.
– notice: Copyright © 2021 Kanno, Chen, Lee, Chiou and Chen 2021 Kanno, Chen, Lee, Chiou and Chen
DBID RYH
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fonc.2021.640392
DatabaseName CiNii Complete
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
ExternalDocumentID oai_doaj_org_article_a5f977622fd04b5283e06c2dde17dd4f
PMC8138159
10_3389_fonc_2021_640392
GrantInformation_xml – fundername: Taipei Medical University
– fundername: Chang Gung Memorial Hospital
– fundername: Ministry of Science and Technology, Taiwan
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
RYH
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c534t-e7e6f0992d2b6325438154b6e79f2bfb24edc54738bfd6df61f30dd193a01b7a3
IEDL.DBID M48
ISSN 2234-943X
IngestDate Wed Aug 27 01:28:21 EDT 2025
Thu Aug 21 13:43:56 EDT 2025
Thu Sep 04 21:43:18 EDT 2025
Thu Apr 24 23:10:49 EDT 2025
Tue Jul 01 04:38:46 EDT 2025
Fri Jun 27 00:10:54 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c534t-e7e6f0992d2b6325438154b6e79f2bfb24edc54738bfd6df61f30dd193a01b7a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Gaurisankar Sa, Bose Institute, India; Amit Joshi, Tata Memorial Hospital, India
This article was submitted to Head and Neck Cancer, a section of the journal Frontiers in Oncology
These authors have contributed equally to this work
Edited by: Erminia Massarelli, City of Hope National Medical Center, United States
ORCID 0000-0002-8358-5408
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2021.640392
PMID 34026617
PQID 2531533767
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_a5f977622fd04b5283e06c2dde17dd4f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8138159
proquest_miscellaneous_2531533767
crossref_citationtrail_10_3389_fonc_2021_640392
crossref_primary_10_3389_fonc_2021_640392
nii_cinii_1871428067850297984
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-05-07
PublicationDateYYYYMMDD 2021-05-07
PublicationDate_xml – month: 05
  year: 2021
  text: 2021-05-07
  day: 07
PublicationDecade 2020
PublicationTitle Frontiers in Oncology
PublicationYear 2021
Publisher Frontiers Media SA
Frontiers Media S.A
Publisher_xml – name: Frontiers Media SA
– name: Frontiers Media S.A
References Hou (B50) 2017; 8
Muhsin (B112) 2004; 3
Roy (B63) 2018; 41
Doong (B23) 1988; 263
Peitzsch (B89) 2019; 11
Jung (B97) 2020; 52
Jordan (B24) 2004; 4
Brito (B27) 2008; 182
Zhang (B60) 2012; 41
Burtness (B124) 2019; 394
Shi (B51) 2017; 90
Mita (B83) 2008; 14
Khan (B54) 2010; 10
Lee (B93) 2014; 234
Thibault (B103) 2018; 8
Bray (B1) 2018; 68
Golubovskaya (B73) 2010; 15
Wyatt (B81) 2009; 66
Kamath (B86) 2005; 280
Vermorken (B7) 2007; 357
Blankenberg (B67) 2011; 197
Lim (B92) 2011; 47
Li (B69) 2020; 13
LaCasse (B99) 2008; 27
Xue (B111) 2013; 24
Kuo (B58) 2007; 26
Fury (B113) 2012; 118
Liu (B52) 2017; 8
MacDonald (B61) 2009; 17
Yusuf (B37) 2003; 3
Xuelei (B40) 2015; 51
Fulda (B64) 2012; 11
Kuang (B47) 2017; 8
Nogales (B25) 1995; 375
Zhang (B34) 2008; 13
Hitt (B9) 2005; 23
Lindahl (B20) 1974; 71
Sun (B116) 2018; 8
Byeon (B77) 2019; 51
Govindan (B88) 2015; 12
Hui (B109) 2002; 8
Tanimoto (B43) 2005; 224
Burtness (B107) 2005; 23
Rathore (B100) 2017; 22
Shen (B59) 2013; 104
Canel (B72) 2006; 12
Li (B105) 2005; 7
Yoon (B46) 2017; 37
Ichim (B68) 2016; 16
Li (B45) 2016; 14
Bharadwaj (B26) 2004; 23
Ilic (B76) 1998; 143
Vasan (B13) 2019; 575
Shostak (B78) 2015; 21
Mizumachi (B55) 2008; 27
Khan (B53) 2009; 31
Zunino (B35) 1999; 2
Chiu (B39) 2011; 9
Kato (B75) 2012; 417
Kavallaris (B85) 1997; 100
Warta (B41) 2014; 9
Salvesen (B65) 2002; 3
Prince (B90) 2007; 104
Ganguly (B29) 2010; 9
Prince (B91) 2008; 26
Vermorken (B108) 2008; 359
McNeil (B96) 2015; 31
Hopper-Borge (B79) 2009; 13
Chow (B3) 2020; 382
Okano (B11) 2021; 51
Nussinov (B80) 2017; 38
Blanchard (B6) 2016; 27
Posner (B8) 2007; 357
Fletcher (B56) 2010; 10
Pfister (B4) 2014; 12
Kelland (B14) 2007; 7
Peng (B120) 2015; 75
Johnson (B2) 2020; 6
Santi (B19) 1974; 13
Chen (B32) 2019; 20
Nagata (B49) 2011; 105
Ishida (B15) 2002; 99
Safaei (B57) 2004; 98
Brands (B102) 2018; 15
Wilhelm (B110) 2006; 5
Lin (B117) 2018; 78
Gong (B82) 2012; 72
Orr (B36) 2003; 22
Yang (B44) 2012; 7
Verweij (B30) 1994; 5
Santi (B22) 1987; 26
Jiang (B66) 2007; 17
Sulzmaier (B70) 2014; 14
Galluzzi (B31) 2014; 5
Ferris (B123) 2018; 81
Yao (B114) 2015; 37
Diaz Osterman (B74) 2019; 8
Chen (B98) 2020; 26
Lim (B94) 2012; 48
Nienstedt (B87) 2017; 46
Rocha (B95) 2018; 73
Sun (B104) 2020; 21
Schwock (B115) 2010; 14
Wohlhueter (B18) 1980; 104
Zhang (B33) 2018; 11
Waters (B28) 1998; 141
Jun (B38) 2008; 99
Liu (B62) 2017; 402
La (B101) 2017; 1
Fennell (B118) 2019; 37
Specenier (B12) 2009; 29
Li (B42) 2016; 2016
Van Der Kraak (B119) 2016; 4
Tran (B121) 2017; 5
Galluzzi (B16) 2012; 31
Ferris (B122) 2016; 375
Hitt (B10) 2002; 13
Chung (B106) 2006; 24
Chung (B48) 2014; 25
Yang (B71) 2019; 19
Okada (B84) 2004; 4
Ghoshal (B21) 1994; 54
Longley (B17) 2003; 3
Pignon (B5) 2009; 92
References_xml – volume: 37
  year: 2015
  ident: B114
  article-title: Phase II Study of Bevacizumab in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
  publication-title: Head Neck
  doi: 10.1002/hed.23813
– volume: 12
  year: 2015
  ident: B88
  article-title: Establishment and Characterization of Triple Drug Resistant Head and Neck Squamous Cell Carcinoma Cell Lines
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2015.3768
– volume: 8
  start-page: e2874
  year: 2017
  ident: B47
  article-title: Bst2 Confers Cisplatin Resistance Via NF-kappaB Signaling in Nasopharyngeal Cancer
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2017.271
– volume: 90
  start-page: 897
  year: 2017
  ident: B51
  article-title: Targeting the Bcl-2 Family and P-glycoprotein Reverses Paclitaxel Resistance in Human Esophageal Carcinoma Cell Line
  publication-title: BioMed Pharmacother
  doi: 10.1016/j.biopha.2017.04.043
– volume: 72
  year: 2012
  ident: B82
  article-title: FoxM1 and Wnt/beta-catenin Signaling in Glioma Stem Cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-0953
– volume: 47
  start-page: 83
  year: 2011
  ident: B92
  article-title: Cancer Stem Cell Traits in Squamospheres Derived From Primary Head and Neck Squamous Cell Carcinomas
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2010.11.011
– volume: 75
  year: 2015
  ident: B120
  article-title: Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression Via the Nuclear Factor-Kappab to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-3098
– volume: 17
  start-page: 9
  year: 2009
  ident: B61
  article-title: Wnt/Beta-Catenin Signaling: Components, Mechanisms, and Diseases
  publication-title: Dev Cell
  doi: 10.1016/j.devcel.2009.06.016
– volume: 118
  year: 2012
  ident: B113
  article-title: A Phase 2 Study of Bevacizumab With Cisplatin Plus Intensity-Modulated Radiation Therapy for Stage Iii/Ivb Head and Neck Squamous Cell Cancer
  publication-title: Cancer
  doi: 10.1002/cncr.27498
– volume: 22
  start-page: 898
  year: 2017
  ident: B100
  article-title: Overcoming Chemotherapy Drug Resistance by Targeting Inhibitors of Apoptosis Proteins (Iaps)
  publication-title: Apoptosis
  doi: 10.1007/s10495-017-1375-1
– volume: 21
  year: 2015
  ident: B78
  article-title: EGFR and NF-kappaB: Partners in Cancer
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2015.04.001
– volume: 9
  start-page: e108908
  year: 2014
  ident: B41
  article-title: Association of Drug Transporter Expression With Mortality and Progression-Free Survival in Stage Iv Head and Neck Squamous Cell Carcinoma
  publication-title: PloS One
  doi: 10.1371/journal.pone.0108908
– volume: 8
  year: 2019
  ident: B74
  article-title: Fak Activity Sustains Intrinsic and Acquired Ovarian Cancer Resistance to Platinum Chemotherapy
  publication-title: Elife
  doi: 10.7554/eLife.47327
– volume: 11
  year: 2018
  ident: B33
  article-title: Activation of C-Jun/JNK Signaling Predicts Poor Prognosis in Nasopharyngeal Carcinoma
  publication-title: Int J Clin Exp Pathol
  doi: 10.3390/molecules13081551
– volume: 8
  year: 2002
  ident: B109
  article-title: Coexpression of Hypoxia-Inducible Factors 1alpha and 2alpha, Carbonic Anhydrase IX, and Vascular Endothelial Growth Factor in Nasopharyngeal Carcinoma and Relationship to Survival
  publication-title: Clin Cancer Res an Off J Am Assoc Cancer Res
– volume: 143
  year: 1998
  ident: B76
  article-title: Extracellular Matrix Survival Signals Transduced by Focal Adhesion Kinase Suppress p53-mediated Apoptosis
  publication-title: J Cell Biol
  doi: 10.1083/jcb.143.2.547
– volume: 46
  year: 2017
  ident: B87
  article-title: High-Level Betaiii-Tubulin Overexpression Occurs in Most Head and Neck Cancers But is Unrelated to Clinical Outcome
  publication-title: J Oral Pathol Med
  doi: 10.1111/jop.12607
– volume: 575
  start-page: 299
  year: 2019
  ident: B13
  article-title: A View on Drug Resistance in Cancer
  publication-title: Nature
  doi: 10.1038/s41586-019-1730-1
– volume: 8
  start-page: e2659
  year: 2017
  ident: B50
  article-title: The FOXM1-ABCC5 Axis Contributes to Paclitaxel Resistance in Nasopharyngeal Carcinoma Cells
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2017.53
– volume: 16
  year: 2016
  ident: B68
  article-title: A Fate Worse Than Death: Apoptosis as an Oncogenic Process
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2016.58
– volume: 10
  year: 2010
  ident: B54
  article-title: Oxaliplatin-Mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/156800910793605866
– volume: 25
  year: 2014
  ident: B48
  article-title: A 3’-Utr KRAS-variant is Associated With Cisplatin Resistance in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdu367
– volume: 38
  year: 2017
  ident: B80
  article-title: A New View of Pathway-Driven Drug Resistance in Tumor Proliferation
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2017.02.001
– volume: 13
  year: 2020
  ident: B69
  article-title: Long Non-Coding Rna DLEU1 Up-Regulates BIRC6 Expression by Competitively Sponging miR-381-3p to Promote Cisplatin Resistance in Nasopharyngeal Carcinoma
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S237456
– volume: 280
  year: 2005
  ident: B86
  article-title: Betaiii-Tubulin Induces Paclitaxel Resistance in Association With Reduced Effects on Microtubule Dynamic Instability
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M414477200
– volume: 4
  year: 2004
  ident: B24
  article-title: Microtubules as a Target for Anticancer Drugs
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1317
– volume: 7
  year: 2007
  ident: B14
  article-title: The Resurgence of Platinum-Based Cancer Chemotherapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2167
– volume: 2016
  start-page: 5378567
  year: 2016
  ident: B42
  article-title: Overexpression of Beta-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma
  publication-title: BioMed Res Int
  doi: 10.1155/2016/5378567
– volume: 5
  start-page: 495
  year: 1994
  ident: B30
  article-title: Paclitaxel (Taxol) and Docetaxel (Taxotere): Not Simply Two of a Kind
  publication-title: Ann Oncol
  doi: 10.1093/oxfordjournals.annonc.a058903
– volume: 375
  year: 2016
  ident: B122
  article-title: Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa1602252
– volume: 51
  start-page: 1
  year: 2019
  ident: B77
  article-title: Beyond EGFR Inhibition: Multilateral Combat Strategies to Stop the Progression of Head and Neck Cancer
  publication-title: Exp Mol Med
  doi: 10.1038/s12276-018-0202-2
– volume: 3
  year: 2002
  ident: B65
  article-title: Iap Proteins: Blocking the Road to Death’s Door
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm830
– volume: 375
  year: 1995
  ident: B25
  article-title: Structure of Tubulin At 6.5 A and Location of the Taxol-Binding Site
  publication-title: Nature
  doi: 10.1038/375424a0
– volume: 382
  start-page: 60
  year: 2020
  ident: B3
  article-title: Head and Neck Cancer
  publication-title: New Engl J Med
  doi: 10.1056/NEJMra1715715
– volume: 14
  start-page: 77
  year: 2010
  ident: B115
  article-title: Targeting Focal Adhesion Kinase Signaling in Tumor Growth and Metastasis
  publication-title: Expert Opin Ther Targets
  doi: 10.1517/14728220903460340
– volume: 394
  year: 2019
  ident: B124
  article-title: Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (Keynote-048): A Randomised, Open-Label, Phase 3 Study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(19)32591-7
– volume: 9
  start-page: 31
  year: 2011
  ident: B39
  article-title: High ERCC1 Expression Predicts Cisplatin-Based Chemotherapy Resistance and Poor Outcome in Unresectable Squamous Cell Carcinoma of Head and Neck in a Betel-Chewing Area
  publication-title: J Transl Med
  doi: 10.1186/1479-5876-9-31
– volume: 1
  year: 2017
  ident: B101
  article-title: Birinapant Sensitizes Platinum-Resistant Carcinomas With High Levels of cIAP to Carboplatin Therapy
  publication-title: NPJ Precis Oncol
  doi: 10.1038/s41698-017-0008-z
– volume: 4
  start-page: 65
  year: 2016
  ident: B119
  article-title: 5-Fluorouracil Upregulates Cell Surface B7-H1 (Pd-L1) Expression in Gastrointestinal Cancers
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-016-0163-8
– volume: 8
  start-page: 2550
  year: 2018
  ident: B116
  article-title: Nuclear FAK and its Kinase Activity Regulate Vegfr2 Transcription in Angiogenesis of Adult Mice
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-20930-z
– volume: 26
  start-page: e923799
  year: 2020
  ident: B98
  article-title: Wnt974 Inhibits Proliferation, Induces Apoptosis, and Enhances Chemosensitivity to Doxorubicin in Lymphoma Cells by Inhibiting Wnt/beta-Catenin Signaling
  publication-title: Med Sci Monit
  doi: 10.12659/MSM.923799
– volume: 99
  year: 2002
  ident: B15
  article-title: Uptake of the Anticancer Drug Cisplatin Mediated by the Copper Transporter Ctr1 in Yeast and Mammals
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.162491399
– volume: 37
  year: 2017
  ident: B46
  article-title: Livin Enhances Chemoresistance in Head and Neck Squamous Cell Carcinoma
  publication-title: Oncol Rep
  doi: 10.3892/or.2017.5584
– volume: 31
  start-page: 19
  year: 2015
  ident: B96
  article-title: Inhibition of the ERCC1-XPF Structure-Specific Endonuclease to Overcome Cancer Chemoresistance
  publication-title: DNA Repair (Amst)
  doi: 10.1016/j.dnarep.2015.04.002
– volume: 141
  year: 1998
  ident: B28
  article-title: Localization of Mad2 to Kinetochores Depends on Microtubule Attachment, Not Tension
  publication-title: J Cell Biol
  doi: 10.1083/jcb.141.5.1181
– volume: 14
  year: 2016
  ident: B45
  article-title: Expression and Clinical Significance of Apollon in Esophageal Squamous Cell Carcinoma
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2016.5473
– volume: 23
  year: 2005
  ident: B107
  article-title: Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.2005.02.4646
– volume: 104
  year: 2007
  ident: B90
  article-title: Identification of a Subpopulation of Cells With Cancer Stem Cell Properties in Head and Neck Squamous Cell Carcinoma
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0610117104
– volume: 2
  year: 1999
  ident: B35
  article-title: Molecular Mechanisms of Resistance to Taxanes and Therapeutic Implications
  publication-title: Drug Resist Updat
  doi: 10.1054/drup.1999.0108
– volume: 20
  year: 2019
  ident: B32
  article-title: New Insights Into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20174136
– volume: 41
  year: 2012
  ident: B60
  article-title: The Expression and Significance of MRP1, Lrp, TOPOIIbeta, and BCL2 in Tongue Squamous Cell Carcinoma
  publication-title: J Oral Pathol Med
  doi: 10.1111/j.1600-0714.2011.01066.x
– volume: 73
  start-page: e478s
  year: 2018
  ident: B95
  article-title: Dna Repair Pathways and Cisplatin Resistance: An Intimate Relationship
  publication-title: Clinics (Sao Paulo)
  doi: 10.6061/clinics/2018/e478s
– volume: 15
  year: 2018
  ident: B102
  article-title: Apoptosis-Sensitizing Activity of Birinapant in Head and Neck Squamous Cell Carcinoma Cell Lines
  publication-title: Oncol Lett
  doi: 10.3892/ol.2018.7783
– volume: 6
  start-page: 92
  year: 2020
  ident: B2
  article-title: Head and Neck Squamous Cell Carcinoma
  publication-title: Nat Rev Dis Primers
  doi: 10.1038/s41572-020-00224-3
– volume: 15
  year: 2010
  ident: B73
  article-title: Focal Adhesion Kinase and P53 Signal Transduction Pathways in Cancer
  publication-title: Front Biosci (Landmark Ed)
  doi: 10.2741/3653
– volume: 17
  year: 2007
  ident: B66
  article-title: p53 and Bad: Remote Strangers Become Close Friends
  publication-title: Cell Res
  doi: 10.1038/cr.2007.19
– volume: 11
  year: 2019
  ident: B89
  article-title: Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma: Identification, Characterization and Clinical Implications
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11050616
– volume: 71
  year: 1974
  ident: B20
  article-title: An N-glycosidase From Escherichia Coli That Releases Free Uracil From Dna Containing Deaminated Cytosine Residues
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.71.9.3649
– volume: 357
  year: 2007
  ident: B7
  article-title: Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa071028
– volume: 7
  year: 2005
  ident: B105
  article-title: Structural Basis for Inhibition of the Epidermal Growth Factor Receptor by Cetuximab
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2005.03.003
– volume: 37
  year: 2019
  ident: B118
  article-title: Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: Command-a Double-Blind, Randomized, Phase Ii Study
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.2018.79.0543
– volume: 9
  year: 2010
  ident: B29
  article-title: Paclitaxel-Dependent Cell Lines Reveal a Novel Drug Activity
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-10-0552
– volume: 8
  start-page: 17862
  year: 2018
  ident: B103
  article-title: DEBIO 1143, an IAP Inhibitor, Reverses Carboplatin Resistance in Ovarian Cancer Cells and Triggers Apoptotic or Necroptotic Cell Death
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-35860-z
– volume: 22
  year: 2003
  ident: B36
  article-title: Mechanisms of Taxol Resistance Related to Microtubules
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206934
– volume: 105
  year: 2011
  ident: B49
  article-title: Overexpression of Ciap2 Contributes to 5-FU Resistance and a Poor Prognosis in Oral Squamous Cell Carcinoma
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.387
– volume: 10
  year: 2010
  ident: B56
  article-title: Abc Transporters in Cancer: More Than Just Drug Efflux Pumps
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2789
– volume: 19
  start-page: 485
  year: 2019
  ident: B71
  article-title: Regulation of Cisplatin-Resistant Head and Neck Squamous Cell Carcinoma by the SRC/ETS-1 Signaling Pathway
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-5664-7
– volume: 26
  year: 1987
  ident: B22
  article-title: Catalytic Mechanism and Inhibition of tRNA (Uracil-5-)Methyltransferase: Evidence for Covalent Catalysis
  publication-title: Biochemistry US
  doi: 10.1021/bi00400a016
– volume: 13
  year: 2002
  ident: B10
  article-title: Induction Chemotherapy With Paclitaxel, Cisplatin and 5-Fluorouracil for Squamous Cell Carcinoma of the Head and Neck: Long-Term Results of a Phase Ii Trial
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdf268
– volume: 51
  year: 2021
  ident: B11
  article-title: Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
  publication-title: Japanese J Clin Oncol
  doi: 10.1093/jjco/hyaa220
– volume: 11
  year: 2012
  ident: B64
  article-title: Targeting IAP Proteins for Therapeutic Intervention in Cancer
  publication-title: Nat Rev Drug Discovery
  doi: 10.1038/nrd3627
– volume: 27
  year: 2008
  ident: B99
  article-title: Iap-Targeted Therapies for Cancer
  publication-title: Oncogene
  doi: 10.1038/onc.2008.302
– volume: 31
  year: 2012
  ident: B16
  article-title: Molecular Mechanisms of Cisplatin Resistance
  publication-title: Oncogene
  doi: 10.1038/onc.2011.384
– volume: 13
  year: 2008
  ident: B34
  article-title: 5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies
  publication-title: Molecules
  doi: 10.3390/molecules13081551
– volume: 21
  year: 2020
  ident: B104
  article-title: Debio 1143 and High-Dose Cisplatin Chemoradiotherapy in High-Risk Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Double-Blind, Multicentre, Randomised, Phase 2 Study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(20)30327-2
– volume: 197
  year: 2011
  ident: B67
  article-title: Multimodality Molecular Imaging of Apoptosis in Oncology
  publication-title: AJR Am J Roentgenol
  doi: 10.2214/AJR.11.6953
– volume: 23
  year: 2004
  ident: B26
  article-title: The Spindle Checkpoint, Aneuploidy, and Cancer
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207374
– volume: 5
  start-page: e1257
  year: 2014
  ident: B31
  article-title: Systems Biology of Cisplatin Resistance: Past, Present and Future
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2013.428
– volume: 8
  year: 2017
  ident: B52
  article-title: Rsf1 Regulates the Proliferation and Paclitaxel Resistance Via Modulating NF-kappaB Signaling Pathway in Nasopharyngeal Carcinoma
  publication-title: J Cancer
  doi: 10.7150/jca.16720
– volume: 12
  year: 2006
  ident: B72
  article-title: Overexpression of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma is Independent of Fak Gene Copy Number
  publication-title: Clin Cancer Res an Off J Am Assoc Cancer Res
  doi: 10.1158/1078-0432.CCR-05-1583
– volume: 13
  year: 2009
  ident: B79
  article-title: Mechanisms of Tumor Resistance to EGFR-targeted Therapies
  publication-title: Expert Opin Ther Targets
  doi: 10.1517/14712590902735795
– volume: 24
  year: 2006
  ident: B106
  article-title: Increased Epidermal Growth Factor Receptor Gene Copy Number is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.2006.07.2587
– volume: 4
  start-page: 592
  year: 2004
  ident: B84
  article-title: Pathways of Apoptotic and non-Apoptotic Death in Tumour Cells
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1412
– volume: 26
  year: 2008
  ident: B91
  article-title: Cancer Stem Cells in Head and Neck Squamous Cell Cancer
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.2007.15.1613
– volume: 14
  year: 2008
  ident: B83
  article-title: Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
  publication-title: Clin Cancer Res an Off J Am Assoc Cancer Res
  doi: 10.1158/1078-0432.CCR-08-0746
– volume: 24
  year: 2013
  ident: B111
  article-title: Phase II Study of Sorafenib in Combination With Cisplatin and 5-Fluorouracil to Treat Recurrent or Metastatic Nasopharyngeal Carcinoma
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mds581
– volume: 104
  year: 1980
  ident: B18
  article-title: Facilitated Transport of Uracil and 5-Fluorouracil, and Permeation of Orotic Acid Into Cultured Mammalian Cells
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.1041040305
– volume: 26
  start-page: 71
  year: 2007
  ident: B58
  article-title: The Roles of Copper Transporters in Cisplatin Resistance
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/s10555-007-9045-3
– volume: 402
  year: 2017
  ident: B62
  article-title: Timeless Confers Cisplatin Resistance in Nasopharyngeal Carcinoma by Activating the Wnt/beta-catenin Signaling Pathway and Promoting the Epithelial Mesenchymal Transition
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2017.05.022
– volume: 357
  year: 2007
  ident: B8
  article-title: Cisplatin and Fluorouracil Alone or With Docetaxel in Head and Neck Cancer
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa070956
– volume: 359
  year: 2008
  ident: B108
  article-title: Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa0802656
– volume: 234
  start-page: 99
  year: 2014
  ident: B93
  article-title: Wnt/Beta-Catenin Signalling Maintains Self-Renewal and Tumourigenicity of Head and Neck Squamous Cell Carcinoma Stem-Like Cells by Activating Oct4
  publication-title: J Pathol
  doi: 10.1002/path.4383
– volume: 3
  start-page: 1
  year: 2003
  ident: B37
  article-title: Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/1568009033333754
– volume: 23
  year: 2005
  ident: B9
  article-title: Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.2004.00.1990
– volume: 66
  year: 2009
  ident: B81
  article-title: Participation of DNA Repair in the Response to 5-Fluorouracil
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-008-8557-5
– volume: 51
  year: 2015
  ident: B40
  article-title: Ercc1 Plays an Important Role in Predicting Survival Outcomes and Treatment Response for Patients With Hnscc: A Meta-Analysis
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2015.02.094
– volume: 263
  year: 1988
  ident: B23
  article-title: 5-Fluorouracil Substitution Alters Pre-Mrna Splicing In Vitro
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)68949-5
– volume: 27
  year: 2008
  ident: B55
  article-title: Increased Mitochondrial Dna Induces Acquired Docetaxel Resistance in Head and Neck Cancer Cells
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210681
– volume: 417
  year: 2012
  ident: B75
  article-title: Ets1 Promotes Chemoresistance and Invasion of Paclitaxel-Resistant, Hormone-Refractory PC3 Prostate Cancer Cells by Up-Regulating MDR1 and MMP9 Expression
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2011.12.047
– volume: 78
  year: 2018
  ident: B117
  article-title: Effect of FAK Inhibitor VS-6063 (Defactinib) on Docetaxel Efficacy in Prostate Cancer
  publication-title: Prostate
  doi: 10.1002/pros.23476
– volume: 48
  year: 2012
  ident: B94
  article-title: All-Trans-Retinoic Acid Inhibits Growth of Head and Neck Cancer Stem Cells by Suppression of Wnt/beta-catenin Pathway
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2012.04.013
– volume: 54
  year: 1994
  ident: B21
  article-title: Specific Inhibition of Pre-Ribosomal Rna Processing in Extracts From the Lymphosarcoma Cells Treated With 5-Fluorouracil
  publication-title: Cancer Res
– volume: 31
  year: 2009
  ident: B53
  article-title: Detection of Survivin and p53 in Human Oral Cancer: Correlation With Clinicopathologic Findings
  publication-title: Head neck
  doi: 10.1002/hed.21071
– volume: 5
  year: 2006
  ident: B110
  article-title: Discovery and Development of Sorafenib: A Multikinase Inhibitor for Treating Cancer
  publication-title: Nat Rev Drug Discovery
  doi: 10.1038/nrd2130
– volume: 3
  year: 2004
  ident: B112
  article-title: Bevacizumab
  publication-title: Nat Rev Drug Discovery
  doi: 10.1038/nrd1601
– volume: 13
  year: 1974
  ident: B19
  article-title: Mechanism of Interaction of Thymidylate Synthetase With 5-Fluorodeoxyuridylate
  publication-title: Biochemistry US
  doi: 10.1021/bi00700a012
– volume: 12
  year: 2014
  ident: B4
  article-title: Head and Neck Cancers, Version 2.2014. Clinical Practice Guidelines in Oncology
  publication-title: J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2014.0142
– volume: 99
  year: 2008
  ident: B38
  article-title: Ercc1 Expression as a Predictive Marker of Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Concurrent Chemoradiation
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6604464
– volume: 68
  start-page: 394
  year: 2018
  ident: B1
  article-title: Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21492
– volume: 29
  year: 2009
  ident: B12
  article-title: Docetaxel, Ifosfamide and Cisplatin (DIP) in Squamous Cell Carcinoma of the Head and Neck
  publication-title: Anticancer Res
– volume: 81
  start-page: 45
  year: 2018
  ident: B123
  article-title: Nivolumab vs Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: 2-Year Long-Term Survival Update of CheckMate 141 With Analyses by Tumor Pd-L1 Expression
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2018.04.008
– volume: 104
  year: 2013
  ident: B59
  article-title: Inhibition of Wnt/beta-catenin Signaling Downregulates P-Glycoprotein and Reverses Multi-Drug Resistance of Cholangiocarcinoma
  publication-title: Cancer Sci
  doi: 10.1111/cas.12223
– volume: 3
  year: 2003
  ident: B17
  article-title: 5-Fluorouracil: Mechanisms of Action and Clinical Strategies
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1074
– volume: 100
  year: 1997
  ident: B85
  article-title: Taxol-Resistant Epithelial Ovarian Tumors are Associated With Altered Expression of Specific Beta-Tubulin Isotypes
  publication-title: J Clin Invest
  doi: 10.1172/JCI119642
– volume: 92
  start-page: 4
  year: 2009
  ident: B5
  article-title: Meta-Analysis of Chemotherapy in Head and Neck Cancer (Mach-Nc): An Update on 93 Randomised Trials and 17,346 Patients
  publication-title: Radiother Oncol J Eur Soc Ther Radiol Oncol
  doi: 10.1016/j.radonc.2009.04.014
– volume: 41
  start-page: 185
  year: 2018
  ident: B63
  article-title: Role of Beta-Catenin in Cisplatin Resistance, Relapse and Prognosis of Head and Neck Squamous Cell Carcinoma
  publication-title: Cell Oncol (Dordr)
  doi: 10.1007/s13402-017-0365-1
– volume: 5
  year: 2017
  ident: B121
  article-title: Cisplatin Alters Antitumor Immunity and Synergizes With PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-17-0235
– volume: 52
  year: 2020
  ident: B97
  article-title: Wnt Signaling in Cancer: Therapeutic Targeting of Wnt Signaling Beyond Beta-Catenin and the Destruction Complex
  publication-title: Exp Mol Med
  doi: 10.1038/s12276-020-0380-6
– volume: 7
  start-page: e31601
  year: 2012
  ident: B44
  article-title: XIAP is a Predictor of Cisplatin-Based Chemotherapy Response and Prognosis for Patients With Advanced Head and Neck Cancer
  publication-title: PloS One
  doi: 10.1371/journal.pone.0031601
– volume: 14
  start-page: 598
  year: 2014
  ident: B70
  article-title: FAK in Cancer: Mechanistic Findings and Clinical Applications
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3792
– volume: 27
  start-page: vi328
  year: 2016
  ident: B6
  article-title: Meta-Analysis of Chemotherapy in Head and Neck Cancer (Mach-Nc): An Update on 100 Randomized Trials and 19,248 Patients, on Behalf of MACH-NC Group
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdw376.02
– volume: 224
  year: 2005
  ident: B43
  article-title: Nuclear Expression of cIAP-1, an Apoptosis Inhibiting Protein, Predicts Lymph Node Metastasis and Poor Patient Prognosis in Head and Neck Squamous Cell Carcinomas
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2004.11.049
– volume: 182
  year: 2008
  ident: B27
  article-title: Microtubules do Not Promote Mitotic Slippage When the Spindle Assembly Checkpoint Cannot be Satisfied
  publication-title: J Cell Biol
  doi: 10.1083/jcb.200805072
– volume: 98
  year: 2004
  ident: B57
  article-title: The Role of Copper Transporters in the Development of Resistance to Pt Drugs
  publication-title: J Inorg Biochem
  doi: 10.1016/j.jinorgbio.2004.05.006
SSID ssj0000650103
Score 2.4602969
SecondaryResourceType review_article
Snippet Chemotherapy resistance is a huge barrier for head and neck cancer (HNC) patients and therefore requires close attention to understand its underlay mechanisms...
SourceID doaj
pubmedcentral
proquest
crossref
nii
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 640392
SubjectTerms chemotherapy
chemotherapy resistance
combination therapy
head and neck cancer
immunotherapy
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Oncology
RC254-282
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV2_b9UwELZQh4oFQQsiQJGRujCElziO7YxQUT0hvQ6ISt0s_ziLCPCrmteB_567JK96WWBhyeA40uXu7Pus833H2LlLXQiNkmX0VShlXfmyMyBxXYFORmBETlSNvLlS62v55aa9OWj1RXfCJnrgSXEr1yaEKEqIFCvpiYoEKhUErspaxygT7b4Yxg4OU9Me3FIDgykviaewbpW2mRgLRf1ByarpxCIOjXT9GF1y3y-Q5vKe5EHguXzKnsyIkX-cJH3GHkE-YcebOSd-ytabfYdbvgGq4-2HXwPfJk5cAHN91W_-FQZCimhi3me-RstylyO_gvCDX9Dw3fCcXV9-_naxLuf-CGVoG7krQYNKiPBEFF41VNVuEBB5BbpLwicvJIpOvYWNT1HFpOrUVDEiZHNV7bVrXrCjvM3wkvFUgYLgETtohxGqddFrj0gqCIBknCnYaq8tG2bycOph8dPiIYL0a0m_lvRrJ_0W7P3DF7cTccZf5n4iAzzMI8rrcQAdwc6OYP_lCAU7Q_OhdPSs8RwoKWmsTUvtuTojC_Zub1iLS4jyIi7D9n6wAvchRL1a6YLphcUXEi3f5P77SMZtatJ69-p__MJr9pi0Mt6n1G_Y0e7uHs4Q8-z829G9_wDqGv41
  priority: 102
  providerName: Directory of Open Access Journals
Title Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers
URI https://cir.nii.ac.jp/crid/1871428067850297984
https://www.proquest.com/docview/2531533767
https://pubmed.ncbi.nlm.nih.gov/PMC8138159
https://doaj.org/article/a5f977622fd04b5283e06c2dde17dd4f
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2234-943X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000650103
  issn: 2234-943X
  databaseCode: KQ8
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2234-943X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000650103
  issn: 2234-943X
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2234-943X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000650103
  issn: 2234-943X
  databaseCode: DIK
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2234-943X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000650103
  issn: 2234-943X
  databaseCode: GX1
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2234-943X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000650103
  issn: 2234-943X
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2234-943X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000650103
  issn: 2234-943X
  databaseCode: RPM
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2234-943X
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0000650103
  issn: 2234-943X
  databaseCode: M48
  dateStart: 20110601
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3Nb9UwDI9gSIgLGl-isE1B4sKhW5umSXqYEEyMJ6TugHjSu0X5hI7RwuubxP772W3foNIElx7SpE3tOP65jm1CXptYOVcInnqbuZTnmU0rFTjIVZBRMdDIEaOR6zOxWPJPq3L1Jzx6ImB_q2mH9aSW64vD37-u3oLAH6PFCfr2KHYtJiNk-aHgGTz9LrkHeonhGq8nsD_uyyUWNRh9lbcOnOmmIYU_aJy2aWboc3528i9ldLpLHk4okr4b2f6I3Dk3j8n9evKTPyGLelv1ltYBY3ub_kdPu0gxP8AUc3VFP4ce0SOwnTYtXQC3qWk9PQvuOz3B5nX_lCxPP3w5WaRTzYTUlQXfpEEGEQH1Mc-sKDDSXQFIsiLIKjIbLeMwdaw3rGz0wkeRxyLzHmCcyXIrTfGM7LRdG54TGrMggrOAJ6QBrVUab6UFdOVYCFEZlZCjLbW0mxKKY12LCw2GBdJXI3010leP9E3Im5sRP8dkGv_o-x4ZcNMP02APDd36q56kSpsyAn4VjEWfcYt5akImHIMtO5fe85iQfWAfzA6vOdiGHB3JUpVYsqtSPCGvtozVIFboKzFt6C57zWBvAiQshUyInHF8NqP5nbb5NiToVjlSvXrxn7e_JA_wg4fjk3KP7GzWl2EfIM7GHgy_BuD6cZUfDKv4Gij3-L8
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+Mechanisms+of+Chemotherapy+Resistance+in+Head+and+Neck+Cancers&rft.jtitle=Frontiers+in+Oncology&rft.au=Yuzuka+Kanno&rft.au=Chang-Yu+Chen&rft.au=Hsin-Lun+Lee&rft.au=Jeng-Fong+Chiou&rft.date=2021-05-07&rft.pub=Frontiers+Media+SA&rft.eissn=2234-943X&rft.volume=11&rft_id=info:doi/10.3389%2Ffonc.2021.640392
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon